Table 2 Baseline characteristics and type of intracranial lesions in patients with TBI with confirmed intracranial lesions stratified by primary referral to a regional or specialised centre, N = 1,180
Variable | Regional Hospital n = 717 (60.8) | Specialised Centre n = 463 (39.2) | p- value |
|---|---|---|---|
Sex, male, n (%) | 449 (62.6) | 309 (66.7) | |
Age, median years [IQR] | 72 [56–81] | 65 [45–76] | < 0.001* |
Charlson Comorbidity Index, n (%) | |||
No | 117 (15.9) | 122 (26.4) | |
Low | 137 (19.1) | 98 (21.2) | |
Medium | 228 (31.8) | 143 (30.9) | |
High | 238 (33.2) | 100 (21.6) | |
Antiplatelet/-coagulant treatment, n (%) | |||
Acetylsalicylic acid | 137 (19.1) | 76 (16.4) | |
ADP-receptor antagonist | 59 (8.2) | 26 (5.6) | |
Vitamin K antagonist | 79 (11.0) | 26 (5.6) | |
NOAC | 50 (7.0) | 33 (7.1) | |
Other | 15 (2.1) | 7 (1.5) | |
Type of intracranial lesion, n (%) | |||
Epidural haemorrhage | 24 (3.4) | 21 (4.5) | |
Subdural haemorrhage | 401 (55.9) | 263 (56.8) | |
Subarachnoid haemorrhage | 93 (13.0) | 78 (16.9) | |
Cerebral Contusion | 85 (11.9) | 27 (5.8) | |
Other | 114 (15.0) | 74 (16.0) |